Podium to Practice: EHA 2025 – Leukemia: TRIPLET COMBINATION IN FLT3-ITD MUTATED AML
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
S142 – PHASE I/II STUDY OF DECITABINE, VENETOCLAX, AND QUIZARTINIB TRIPLET COMBINATION IN FLT3-ITD MUTATED AML
Studies/trials discussed:
S142 – PHASE I/II STUDY OF DECITABINE, VENETOCLAX, AND QUIZARTINIB TRIPLET COMBINATION IN FLT3-ITD MUTATED AML
199 Bay Street #4000
Toronto, ON M5L 1A9
©2025 OncologyEducation a Think Research company. All rights reserved. Privacy Policy. Privacy Notice. Accessibility Statement.
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.